Author

Viswanath Devanarayan

University of Illinois ChicagoORCID 0000-0003-2059-9252Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:benchmarking· 1 Assay:proteomics· 1

Frequent Co-Authors

Daniel A. LlanoiD· 3 shared Priya Devanarayan· 3 shared Alzheimer’s Disease Neuroimaging Initiative· 1 shared for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)· 1 shared Lina K. IssaiD· 1 shared the Alzheimer’s Disease Neuroimaging Initiative (ADNI)· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

6 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Daniel A. LlanoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NeuroscienceCellsPeer-reviewedNov 28, 2020

Hearing loss in Alzheimer Disease is associated with altered serum lipidomic biomarker profiles

Daniel A. Llano, Lina K. Issa, Priya Devanarayan…·Alzheimer’s Disease Neuroimaging Initiative

The paper investigates serum lipidomic profiles in Alzheimer Disease patients with and without hearing loss, finding altered phosphatidylcholine levels associated with hearing loss.

25 citations

humanbulk RNA-seq

𝕏 PostBluesky

NeuroscienceAlzheimer Disease & Associated DisordersPeer-reviewedJul 12, 2019

VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimer Disease.

Daniel A. Llano, Priya Devanarayan, Viswanath Devanarayan, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

This study shows that adding VGF peptide levels to conventional biomarkers improves prediction of conversion from mild cognitive impairment to Alzheimer's Disease.

35 citations

humanproteomics

𝕏 PostBluesky

NeuroscienceJournal of Alzheimer s DiseasePeer-reviewedFeb 12, 2019

Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer disease progression that reinforces the 2018 NIA-AA research framework

Priya Devanarayan, Viswanath Devanarayan, Daniel A. Llano, the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

The paper identifies a novel 4-marker CSF and MRI signature for predicting Alzheimer's disease progression, reinforcing the 2018 NIA-AA framework with improved accuracy over conventional markers.

18 citations

humanbulk RNA-seq

𝕏 PostBluesky